行情

NMTR

NMTR

9 Meters Biopharma
NASDAQ

实时行情|Nasdaq Last Sale

0.7500
+0.0015
+0.20%
盘后: 0.7700 +0.02 +2.67% 18:31 01/24 EST
开盘
0.7330
昨收
0.7485
最高
0.7650
最低
0.7185
成交量
265.06万
成交额
--
52周最高
2.260
52周最低
0.7185
市值
1.92亿
市盈率(TTM)
-5.2484
分时
5日
1月
3月
1年
5年
9 meters Bio secures new U.S. patent for NM-102 + immune checkpoint inhibitors
9 Meters Biopharma (NASDAQ:NMTR) has received notice from the USPTO that U.S. Patent Application No. 17/239,056 is allowed. The patent demonstrates that NM-102, which can prevent disruption of and/or restore
Seekingalpha · 11小时前
BRIEF-9 Meters Biopharma Announces Allowance Of Patent For NM-102 In Combination With Immune Checkpoint Inhibitors
reuters.com · 11小时前
9 Meters Biopharma's Patent for NM-102 Approved
The patent demonstrates that NM-102, which can prevent disruption of and/or restore the functional integrity of the ileal and/or colonic intestinal barrier, can improve the benefit of immune checkpoint inhibitors (ICIs)
Benzinga · 12小时前
9 Meters Biopharma Announces Allowance of Patent for NM-102 in Combination with Immune Checkpoint Inhibitors
RALEIGH, NC / ACCESSWIRE / January 24, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today that the Company has received notice from th...
ACCESSWIRE · 12小时前
9 Meters Biopharma Gets US Notice of Allowance for Patent Covering NM-102 Cancer Therapy
MT Newswires · 14小时前
Raleigh public company adds former Biogen exec to suite
A relatively new biopharmaceutical company in Raleigh has added a new name to its C-suite. 9 Meters Biopharma (Nasdaq: NMTR) has appointed Bethany Sensenig to be chief financial officer. Sensenig is joining the clinical-stage company, which is focused on...
American City Business Journals · 3天前
BRIEF-9 Meters Biopharma Inc - Appoints Bethany Sensenig As CFO
reuters.com · 6天前
9 Meters Biopharma Appoints Bethany Sensenig as Chief Financial Officer
Formerly served as VP of Finance and Commercial Operations at Biogen with 20+ years of business and strategic financial leadership experienceRALEIGH, NC / ACCESSWIRE / January 18, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pion...
ACCESSWIRE · 6天前
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解NMTR最新的财务预测,通过NMTR每股收益,每股净资产,每股现金流等数据分析9 Meters Biopharma近期的经营情况,然后做出明智的投资选择。
分析师评级

5位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

40.00%强力推荐
60.00%买入
0.00%中性
0.00%落后大盘
0.00%卖出
目标价格预测
分析师预测NMTR价格均价为5.25,最高价位6.00,最低价为5.00。
最高6.00
均价5.25
最低5.00
现价0.7500
EPS
实际EPS
预期EPS
-0.04-0.03-0.02-0.01
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
机构持股
总机构数: 110
机构持股: 7,278.41万
持股比例: 28.47%
总股本: 2.56亿
类型机构数股数
增持
28
462.63万
建仓
18
470.37万
减持
21
832.83万
平仓
11
275.19万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
+1.12%
制药与医学研究
-0.55%
高管信息
Non-Executive Chairman/Independent Director
Mark Sirgo
President/Chief Executive Officer/Director
John Temperato
Chief Financial Officer
Edward Sitar
Other
Sarah Liu
Independent Director
Michael Constantino
Independent Director
Lorin Johnson
Independent Director
Michael Rice
Independent Director
Samantha Ventimiglia
暂无数据
NMTR 简况
9 Meters Biopharma Inc(原名:Innovate Biopharmaceuticals Inc)是一家胃肠平台公司。该公司从事为罕见疾病和未满足需求的患者开发治疗方案。其产品包括短肠综合征和腹腔疾病候选药物,以及NM-002、Larazotide、NM-003和NM-004。NM-002是用于短肠综合征(SBS)的长效可注射GLP-1类似物。Larazotide是用于腹腔疾病的口服和肠道受限的紧密连接调节剂。NM-003是处于罕见药下的GLP-2类似物。NM -004是一种免疫调节剂,在溃疡性结肠炎中被称为儿科罕见药。

微牛提供9 Meters Biopharma Inc(NASDAQ-NMTR)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的NMTR股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易NMTR股票基本功能。